Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HeVacc: Heterologous Vaxzevria and Comirnaty Vaccination
NCT04907331Phase 2Unknown
- Sponsor
- Medical University of Innsbruck
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Viral Vector Vaccines, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ChAdOx1 nCoV-19, tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Medical University of Innsbruck. Status: unknown.
02
Drugs
ChAdOx1 nCoV-19tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04907331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907331.